Latest Research And Development News

Activeport Group Ltd reported steady Q1 FY26 results with key project deliveries and a successful capital raise, positioning the company for accelerated growth across Asia and beyond.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for chronic wound treatment and advances regulatory filings for its TR Pro+® product, while gearing up for a major commercial rollout in early 2026.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Australian Rare Earths Limited (ASX, AR3) reported strong progress in its Koppamurra Rare Earths Project with high recovery rates and production milestones, while also expanding and resuming drilling at its Overland Uranium Project. The company bolstered its financial position through government grants and option exercises.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

LTR Pharma has made significant strides towards its US market debut with ROXUS, bolstered by expert appointments and peer-reviewed clinical data validating its rapid-onset ED treatments.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Nexus Minerals has reported significant new high-grade gold discoveries at its Wallbrook Gold Project, alongside progress in permitting its Crusader-Templar deposit for mining operations.

MyEco Group reported a modest 2% sales increase in Q1 FY26, driven by strong council channel growth that offsets U.S. tariff-related setbacks. Operational restructuring and regulatory tailwinds underpin its medium-term outlook.

Parkway Corporate Limited reports a robust start to FY26 with strong operating revenue and EBITDA, alongside securing a pivotal 10-hectare site for its Queensland Brine Management Complex project.

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

Assetora Limited disclosed a $341,000 net operating cash outflow for the September 2025 quarter, supported by $1.6 million in total available funding including cash reserves and financing facilities.